• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经肿瘤学中的患者报告结局。

Patient-reported outcomes in neuro-oncology.

机构信息

Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.

出版信息

Curr Opin Oncol. 2024 Nov 1;36(6):560-568. doi: 10.1097/CCO.0000000000001078. Epub 2024 Jul 10.

DOI:10.1097/CCO.0000000000001078
PMID:38984633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11460742/
Abstract

PURPOSE OF REVIEW

To provide up-to-date evidence on patient-reported outcomes (PROs) in neuro-oncology, with a focus on the core constructs of health-related quality of life (HRQoL) and the use of PROs in clinical trials and clinical practice.[Supplemental Digital Content: Video Abstract PROs in Neuro-Oncology.mov].

RECENT FINDINGS

PROs are gaining importance in brain tumor research and medical care. For patients with a brain tumor, core PRO constructs are pain, difficulty communicating, perceived cognition, seizures, symptomatic adverse events, physical functioning and role and social functioning, which are assessed through patient-reported outcome measures (PROMs). Initiatives have been taken to improve the reliability and robustness of PRO data, including standardization of items included in clinical trial protocols (the SPIRIT-PRO extension) and formulation of PRO priority objectives for use in clinical trials (the SISAQOL-Innovative Medicines Initiative). In brain tumor patients with cognitive impairment, caregiver-reported outcomes may complement or replace PROs to increase accuracy. The next key challenge will be to widely implement PROs and apply PRO data in clinical practice to benefit patients with brain tumors.

SUMMARY

PROs are clinically relevant endpoints providing information only known by the patient. Standardization of the use of PROs in clinical trials and wide implementation in clinical practice is needed to improve HRQoL of brain tumor patients.

摘要

目的综述

提供神经肿瘤学中患者报告结局(PROs)的最新证据,重点关注健康相关生活质量(HRQoL)的核心构念以及 PROs 在临床试验和临床实践中的应用。[补充数字内容:视频摘要 PROs in Neuro-Oncology.mov]。

最近的发现

PROs 在脑肿瘤研究和医疗保健中越来越重要。对于脑肿瘤患者,核心 PRO 构念包括疼痛、沟通困难、感知认知、癫痫发作、症状性不良事件、身体功能、角色和社会功能,这些通过患者报告结局测量(PROMs)进行评估。已经采取了一些措施来提高 PRO 数据的可靠性和稳健性,包括在临床试验方案中纳入项目的标准化(SPIRIT-PRO 扩展)和制定用于临床试验的 PRO 优先目标(SISAQOL-创新药物倡议)。在认知障碍的脑肿瘤患者中,照顾者报告的结局可能会补充或替代 PROs,以提高准确性。下一个关键挑战将是广泛实施 PROs 并将 PRO 数据应用于临床实践,以使脑肿瘤患者受益。

总结

PROs 是具有临床意义的终点,提供了只有患者才知道的信息。需要标准化 PROs 在临床试验中的应用,并在临床实践中广泛实施,以提高脑肿瘤患者的 HRQoL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a0/11460742/838c6f485608/coonc-36-560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a0/11460742/838c6f485608/coonc-36-560-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49a0/11460742/838c6f485608/coonc-36-560-g001.jpg

相似文献

1
Patient-reported outcomes in neuro-oncology.神经肿瘤学中的患者报告结局。
Curr Opin Oncol. 2024 Nov 1;36(6):560-568. doi: 10.1097/CCO.0000000000001078. Epub 2024 Jul 10.
2
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.患者报告结局纳入临床试验方案指南:SPIRIT-PRO 扩展
JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.
3
Patient-reported outcomes and measures are under-utilised in advanced therapy medicinal products trials for orphan conditions.在针对罕见病的先进治疗药物试验中,患者报告的结局和测量指标未得到充分利用。
J Clin Epidemiol. 2025 Feb;178:111617. doi: 10.1016/j.jclinepi.2024.111617. Epub 2024 Nov 26.
4
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.设定癌症临床试验中分析患者报告结局和生活质量终点的国际标准——创新药物倡议(SISAQOL-IMI):利益相关者的观点、目标和程序。
Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2.
5
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.胶质母细胞瘤患者报告结局评估在临床护理和研究中的应用:神经肿瘤学协作组的报告。
Lancet Oncol. 2020 Feb;21(2):e97-e103. doi: 10.1016/S1470-2045(19)30796-X.
6
Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.脑肿瘤成人患者报告结局测量使用的工作方案:神经肿瘤学反应评估(RANO)倡议。
Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4.
7
Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.卵巢癌临床试验中的患者报告结局(PRO)——错失的机会和吸取的教训。
Ann Oncol. 2016 Apr;27 Suppl 1:i66-i71. doi: 10.1093/annonc/mdw080.
8
Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.评估导致一线免疫检查点阻断联合治疗晚期肾细胞癌患者获批的临床试验中患者报告结局(PROs)方案内容和报告情况——患者的呼声还是错失的机会。
Clin Genitourin Cancer. 2022 Apr;20(2):e158-e165. doi: 10.1016/j.clgc.2021.12.002. Epub 2021 Dec 10.
9
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.单臂研究中涉及肿瘤患者报告结局数据:当前实践的文献综述。
Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9.
10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.

引用本文的文献

1
Clinical trial design for novel targeted agents in neuro-oncology.神经肿瘤学中新型靶向药物的临床试验设计
J Neurooncol. 2025 Jan;171(1):21-33. doi: 10.1007/s11060-024-04846-5. Epub 2024 Oct 8.